Interferon-alpha-Induced Hepatitis C Virus Clearance Restores p53 Tumor Suppressor More Than Direct-Acting Antivirals

Yucel Aydin,1 Animesh Chatterjee,2 Partha K Chandra,2 Srinivas Chava,2 Weina Chen,2 Anamika Tandon,2 Asha Dash,2 Milad Chedid,2 Martin W Moehlen,1 Frederic Regenstein,1 Luis A Balart,1 Ari Cohen,3 Hua Lu,4 Tong Wu,2 and Srikanta Dash1,2

The mechanism why hepatitis C virus (HCV) clearance by direct-acting antivirals (DAAs) does not eliminate the risk of hepatocellular carcinoma (HCC) among patients with advanced cirrhosis is unclear. Many viral and bacterial infections degrade p53 in favor of cell survival to adapt an endoplasmic reticulum (ER)-stress response. In this study, we examined whether HCV clearance by interferon-alpha or DAAs normalizes the ER stress and restores the expression of p53 tumor suppressor in cell culture. We found that HCV infection induces chronic ER stress and unfolded protein response in untransformed primary human hepatocytes. The unfolded protein response induces chaperone-mediated autophagy (CMA) in infected primary human hepatocytes and Huh-7.5 cells that results in degradation of p53 and induced expression of mouse double minute 2 (Mdm2). Inhibition of p53/Mdm2 interactions by small molecule (nutlin-3) or silencing Mdm2 did not rescue the p53 degradation, indicating that HCV infection induces degradation of p53 independent of the Mdm2 pathway. Interestingly, we found that HCV infection degrades p53 in a lysosome-dependent mechanism because lysosome-associated membrane protein 2A silencing restored p53 degradation. Our results show that HCV clearance induced by interferon-alpha-based antiviral therapies normalizes the ER-stress response and restores p53, whereas HCV clearance by DAAs does neither. We show that decreased expression of p53 in HCV-infected cirrhotic liver is associated with expression of chaperones associated with ER stress and the CMA response. Conclusion: HCV-induced ER stress and CMA promote p53 degradation in advanced liver cirrhosis. HCV clearance by DAAs does not restore p53, which provides a potential explanation for why a viral cure by DAAs does not eliminate the HCC risk among patients with advanced liver disease. We propose that resolving the ER-stress response is an alternative approach to reducing HCC risk among patients with cirrhosis after viral cure. (Hepatology Communications 2017;1:256-269)

Introduction

Chronic hepatitis C virus (HCV) infection is the major risk factor for hepatocellular carcinoma (HCC) in the United States. The risk is increased several fold among patients with advanced liver cirrhosis. The recent development of potent direct-acting antivirals (DAAs) is changing the therapeutic options for curing chronic HCV infection, and additional versions of highly effective DAA combination therapies are expected to be available in the future. This provides hope that HCV infection can be globally
eliminated and will require that all infected patients receive early diagnosis and access to antiviral treatment. However, individuals who are chronically infected but remain untreated have the highest risk of developing liver cirrhosis and HCC. Recent clinical studies show that an HCV cure using DAA-based antiviral therapy among patients with advanced liver cirrhosis does not eliminate HCC risk.\(^1\) The incidence of HCC after a viral cure with a DAA-based therapy was found to be much higher than that of the earlier findings with an interferon (IFN)-based antiviral therapy.\(^4\) The mechanism by which HCV cleared by an IFN-based antiviral therapy provides benefits in HCC reduction is unknown, but understanding the basic mechanism of how HCV actually causes HCC could answer this question and therefore remains an important area of future research.

HCV is a positive-strand, enveloped, RNA virus that replicates exclusively in the cytoplasm without integration into the host cell genome. Sustained RNA translation and replication in the hepatocytes results in an accumulation of large amounts of viral proteins in the endoplasmic reticulum (ER), which generates a substantial amount of stress response called the unfolded protein response (UPR). The UPR is orchestrated by three different cellular transcription factors: protein kinase-like endoplasmic reticulum kinase (PERK), activation of transcription factor 6 (ATF6), and inositol-requiring enzyme 1 (IRE1). These transcription factors maintain ER homeostasis. In general, infected hepatocytes cope with ER stress in four steps.\(^5\)

First, infected cells induce transcription of UPR to reduce the protein load in the ER. Second, the UPR improves ER function through inducing chaperone gene expression. Third, proliferation of ER compartments accommodates the viral protein load through initiating ER-associated degradation (ERAD) of unfolded proteins. The UPR uses two types of ERAD mechanisms: ubiquitin-proteasome-dependent degradation (type I) and autophagy-dependent lysosomal degradation (type II). Fourth, if the ERAD response fails to resolve the ER stress associated with the virus infection, then the UPR switches from cellular prosurvival signaling to apoptosis signaling. Infected cells also use different cellular surveillance mechanisms to block virus replication and spread.\(^6\)

One such mechanism involves the production of IFN, which directly inhibits virus replication.\(^7\) The other mechanism involves blocking the spread of infection by inducing p53-mediated cellular apoptosis.\(^8\)

Over the past several years, many investigators, including our own, showed that HCV-associated ER stress induced an autophagy response, which results in impaired host innate immunity through blocking endogenous IFN production\(^7\) and also escapes from exogenously added IFN-\(\alpha\) and ribavirin (RBV)-based antiviral therapy through degradation of interferon-\(\alpha\) receptor 1 and RBV transporter.\(^10\) In this report, we found that HCV infection induces chaperone-mediated autophagy (CMA) as a cell survival mechanism to avoid the ER-stress response. Our results show that HCV degrades both mutant p53 in a proliferative Huh-7.5 culture and wild-type p53 in a nonproliferative primary human hepatocytes (PHHs).
culture using a mechanism that is independent of mouse double minute 2 (Mdm2). As the loss of p53 function is associated with HCC, our findings provide an explanation for why HCV clearance by DAAs does not eliminate the HCC risk among patients with advanced cirrhosis due to unresolved ER stress. In this study, we compared the restoration of the p53 tumor expression and stress response after viral eradication by interferon versus DAA therapies to determine whether unresolved ER stress could be one of the causes of HCC risk among patients with cirrhosis.

**Materials and Methods**

**PRIMARY HUMAN HEPATOCYTES**

PHHs were obtained from XenoTech, LLC (Kansas City, MO) and cultured with hepatocyte culture media supplemented with 10% human serum (Invitrogen, Brown Deer, WI). After 24 hours, they were infected with cell culture-grown HCV (JFH-DV3-Rluc virus, HCV genotype 2a) with a multiplicity of infection (MOI) of 0.1, using a standard protocol of our laboratory. After 18 hours of infection, hepatocytes were replaced with fresh hepatocyte culture media (XenoTech) supplemented with 10% human serum (Invitrogen). Uninfected or infected PHHs were harvested every 3 days, and cell pellets were used for RNA isolation and western blot analysis. The success of HCV replication in the infected PHHs was assessed by the detection of positive-strand HCV RNA levels by reverse transcription (RT) real-time quantitative polymerase chain reaction (PCR) and western blot analysis of HCV NS3 protein.

**PATIENTS AND LIVER SAMPLES**

A total of 16 explant livers (eight HCV infected with liver cirrhosis, eight HCV-negative HBV-negative explant livers with cirrhosis) were collected from the Ochsner Medical Center (New Orleans, LA) for this study. The liver tissues derived from HCV-negative and HBV-negative patients with a history of alcohol intake; cryptogenic cirrhosis as well as nonalcoholic steatohepatitis were used as control. Explant liver tissues were collected with institutional review board approval from Tulane University Health Sciences Center and Ochsner Medical Center. Informed written consent was obtained from each patient.

**STATISTICAL ANALYSIS**

The immunostaining and immunofluorescence images were quantified using a computer image analysis software package (ImageJ; National Institutes of Health, Bethesda, MD). All measurements were made at least in triplicate (n = 3). To compare means within groups, we performed one-factor analysis of variance (ANOVA) using the GraphPad Prism software. We assumed that all measurements have normal probability distributions, which is expected for these types of data. When the overall P value for the ANOVA analysis was significant (P < 0.05), we applied Dunnet’s post hoc test to compare control samples with experimental samples. When performing comparisons between multiple groups, each analyzed with ANOVA, we used the Bonferroni correction to determine a revised cutoff for statistical significance that gives a combined 5% type I error probability (*P < 0.05, **P < 0.005, ***P < 0.0005).

**Results**

**PERSISTENT HCV REPLICATION INDUCED CHRONIC ER STRESS IN HEPATOCYTES**

To study the effect of HCV replication on hepatocyte growth and survival, we developed a replication model in nonproliferative PHHs. PHHs seeded in a six-well tissue culture plate without collagen were infected with JFH-DV3-Rluc virus (MOI 0.1) overnight. Replication of HCV in PHHs was confirmed by the measurement of viral NS3 protein by western blot analysis (Fig. 1A) and immunostaining for viral core protein (Fig. 1D) and western blot for NS3 protein (Fig. 1E). HCV RNA translation, replication, and virus assembly occurs at the ER and the ER-derived membranes. Accumulation of large amounts of viral proteins during persistent replication induces a stress response in infected PHHs. Prior studies have shown that the UPR was either partially activated or suppressed to attenuate ER-stress-mediated hepatocellular apoptosis using transformed hepatoma cells (Huh-7.5) soon after virus infection. (9,10) It is
unclear whether persistent HCV replication induced chronic or adaptive ER stress in untransformed hepatocytes. Using an HCV-infected PHH model, we found that the expression of all three branches of the UPR were induced and autophagy markers were also induced by western blot analysis for 15 days (Fig. 2A). We noticed that the expression of UPR markers remained high in the infected culture over 15 days compared to uninfected PHHs, indicating that HCV replication induces chronic ER stress. The UPR results in the production of chaperone to increase the folding capacity of the ER and also enhances the ERAD pathway and autophagy. We found that the autophagy response is induced in PHHs secondary to ER stress, which was confirmed by the measurement of autophagy-related 5 and light chain 3B-II levels by western blot analysis (Fig. 2A).

We did not see any significant activation of ER-stress markers in uninfected PHHs when cultured for similar time points without HCV infection (Fig. 2B). The status of the ER-stress/UPR response was examined by comparing the expression of binding immunoglobulin protein (BIP), ATF6, and IRE1α in Huh-7.5 cells with or without HCV infection for similar time periods (Fig. 2C,D). These results are consistent with PHHs, which indicate that HCV infection induces chronic ER stress and the UPR response.

**PERSISTENT HCV INFECTION ACTIVATES CMA**

CMA is responsible for degradation of cytosolic proteins induced under ER-stress conditions through
the PERK and IRE1 axes of the UPR.\textsuperscript{(14,15)} All CMA substrates contain a consensus pentapeptide motif (KFERQ) that is recognized by a cytosolic chaperone; for example, heat shock cognate protein complex 70 (HSC70) binds to lysosome-associated membrane protein 2A (LAMP-2A), which results in the direct translocation of unfolded protein substrate across lysosomal membranes and subsequent degradation. The expression of HSC70 and LAMP-2A has been shown to be the rate-limiting step for the uptake of cellular substrates by lysosome-mediated protein degradation during the process of CMA. Western blot analysis shows that LAMP-2A and HSC70 expression in PHHs was induced nicely after HCV infection. The expression of LAMP-2A and HSC70 in HCV-infected Huh-7.5 cells was confirmed by immunostaining (Fig. 3A). Immunostaining verified the induced expression of LAMP-2A and HSC70 in infected PHHs at days 0, 3, and 15 (Fig. 3B). The immunostaining data were quantified using ImageJ software and were significantly induced after HCV infection (Fig. 3C). The impact of HCV replication on the expression of HSC70 and LAMP-2A was examined in infected Huh 7.5 cell culture after day 9 and were maintained steadily throughout the infection. The expression of LAMP-2A and HSC70 in HCV-infected Huh 7.5 cells was confirmed by immunostaining (Fig. 3E). LAMP-2A and HSC70 expression was quantified using ImageJ software and was found to be induced after HCV infection (Fig. 3F). These results suggest that CMA is induced due to the accumulation of misfolded proteins in the ER during HCV replication.
PERSISTENT HCV INFECTION DEGRADES WILD-TYPE p53 IN PHHs

The p53 protein is induced during cellular stress, leading to transcriptional up-regulation of genes that are involved in the regulation of apoptosis, proliferation, metabolism, and immune response. The expression level of p53 protein is regulated by Mdm2-mediated proteosome degradation.\(^{16}\) A recent publication showed that p53 is a target of CMA because p53 harbors two pentapeptide motifs (200 NLRVE204 and 341FRELN345) that are similar to the HSC70 recognition sequence.\(^{17}\) We examined whether HCV-induced CMA degrades wild-type p53 in infected PHHs. The expression of p53, Mdm2, and p21 levels was examined in HCV-infected PHHs by western blot analysis (Fig. 4A). A significant decrease in p53 expression was found to be associated with an increased level of Mdm2 and decreased expression of p21 in HCV-infected PHHs. PHHs cultured under similar conditions over 15 days showed stable expression of p53, suggesting that the degradation of wild-type p53 is not related to \textit{in vitro} culture. The expression of p53 and p21 was induced and Mdm2 level decreased when PHHs were cultured at similar time points without HCV infection (Fig. 4B). We then examined the impact of infection on transcription of p53, p21, and Mdm2 levels by real-time RT-PCR. Results shown in Fig. 4C indicate that HCV infection induces transcription of p53, p21, and Mdm2 messenger RNA (mRNA) with time. There was an inverse relationship between protein and mRNA expression levels of p53 and p21 but a direct relationship with Mdm2. These results indicate that the decrease in the level of wild-type p53 is due to protein degradation.

To confirm that persistent HCV replication in Huh-7.5 cells also degrades mutant p53 protein by CMA, the expression of p53 was examined by western blot analysis. p53 levels were induced during early stages of infection (0-6 days), and the levels of p53 then significantly decreased after day 9 (Fig. 5A). We found that loss of p53 is associated with increased expression of Mdm2 and decreased expression of p21. The level of p14ARF expression was also decreased after HCV infection. The variation of p53 expression was not due to a lack of adequate amounts of protein in the lysate because levels of tubulin were comparable.
among samples. Real-time RT-PCR results showed that mRNA levels of p53, Mdm2, and p21 increased in the infected culture, excluding the possibility that loss of p53 was not at the level of decreased mRNA transcription (Fig. 5B). The mRNA expression of p53 and p21 was inversely correlated with protein levels, whereas protein and mRNA levels of Mdm2 were induced after virus infection. The expression levels of p53, p21, and Mdm2 proteins in the infected Huh7.5 cells at day 15 were examined by immunocytochemical staining (Fig. 5C). Quantification of immunostaining data showed that the expression of p53 and p21 was decreased significantly with the HCV core expression, whereas the Mdm2 protein expression was induced (Fig. 5D).

**ER STRESS AND AUTOPHAGY DEGRADES p53 INDEPENDENT OF Mdm2**

We also noticed that treatment of ER-stress inducer, the luminal Ca²⁺ mobilizing agent thapsigargin (TG), promotes p53 degradation in HCV-infected culture in a concentration-dependent manner (Supporting Fig. S1A). We showed that autophagy induction in HCV culture by torin-1 treatment (a mammalian target of rapamycin inhibitor) increased degradation of p53 in a concentration-dependent manner (Supporting Fig. S1B). We tested whether the loss of p53 expression by HCV-induced ER stress/CMA could be restored by using an ER-stress inhibitor (tauroursodeoxycholic acid [TUDCA]) or a lysosome inhibitor (hydroxychloroquine [HCQ]). For this purpose, an HCV-infected culture at day 15 (p53 negative) was treated with an increasing concentration of TUDCA or HCQ, and the expression of p53 was examined by western blot analysis (Supporting Fig. S1C,D). The expression of HCV core protein levels in infected Huh-7.5 cells did not change significantly during the TG, torin-1, and TUDCA treatments. Mdm2 is a really interesting new gene finger domain-containing protein that is known to degrade p53 through the ubiquitin-proteasome pathway. Because Mdm2 levels are nicely induced in HCV-infected culture, we speculated that Mdm2 might be involved in the degradation of p53.
It is known that Mdm2-mediated degradation of p53 is dependent on the direct interaction of these two proteins, so we examined whether disruption of the interaction between p53 and Mdm2 by using inhibitor nutlin-3 could result in p53 stabilization in HCV cell culture. It is also known that p53 is degraded through ubiquitin-proteasome pathways and that MG132 is an inhibitor of proteasome-mediated proteolysis that has been used extensively as an inhibitor for stabilization of p53. We found that treatment with either nutlin-3 or MG132 alone or in combination did not stabilize p53 expression levels in HCV-infected culture (Supporting Fig. S1E). These results were also confirmed by fluorescence microscopy after double staining. We found that the nuclear expression of p53 was minimal in HCV-infected Huh-7.5 cells and that the expression was not induced in nutlin-3-treated and MG132-treated culture but was induced in HCQ-treated culture, indicating that p53 degradation is independent of Mdm2-mediated degradation. Restoration of p53 by HCQ suggests that degradation of p53 is through the lysosomal pathway (Supporting Fig. S2). The expression of p53 was monitored with red fluorescence by using Alexa Fluor 647 goat anti-rabbit immunoglobulin G (Invitrogen), and cytoplasmic HCV expression was monitored by green fluorescence protein (GFP) expression using an HCV-GFP chimera virus. The GFP and red fluorescence were quantified using ImageJ software. This analysis revealed that HCV replication decreased expression of p53 and nutlin3a and that MG132 treatment did not restore its expression but HCQ restored p53 expression significantly (Supporting Fig. S2B).

The Mdm2-independent degradation of p53 in HCV culture was also confirmed by two different approaches, inhibition of Mdm2 by small molecules and silencing by small interfering RNA (siRNA). Because the cyclin-dependent kinase inhibitor roscovitine has been shown to suppress the expression of Mdm2, we examined the effect of Mdm2 suppression on the stability of p53 in uninfected and HCV-infected culture. Inhibition of Mdm2 by roscovitine
stabilizes p53 in uninfected Huh-7.5 cells (Supporting Fig. S3A), but inhibition of Mdm2 levels in HCV culture under similar treatment did not stabilize p53 levels (Supporting Fig. S3B). In addition, transfection of Mdm2 siRNA in HCV-infected culture decreased Mdm2 expression but did not stabilize p53 expression in HCV-infected culture, suggesting that degradation of p53 in HCV culture occurs in an Mdm2-independent manner (Supporting Fig. S3C). Interestingly, silencing of LAMP-2A by siRNA transfection stabilizes p53 expression, suggesting that the loss of p53 in HCV culture occurs through lysosome-mediated degradation (Supporting Fig. S3D).

SERUM STARVATION DEGRADES p53 AND SILENCING LAMP-2A PREVENTS p53 DEGRADATION IN Huh-7.5 CELLS

Serum starvation is one of the established experimental models that have been used by many investigators to activate CMA. Uninfected Huh-7.5 cells were cultured in serum-free media for 0, 16, 24, and 48 hours, and the expression of mutant p53 was examined by western blot analysis (Supporting Fig. S4A). We found that p53 expression was significantly diminished after 16 hours of serum starvation and that this had no effect on the expression of Mdm2 levels. Serum starvation also induced the expression of LAMP-2A and HSC70 in Huh.7.5 cells. Silencing LAMP-2A stabilized p53 expression under the serum starvation condition (Supporting Fig. S4B). We then examined whether p53 protein interacted with the CMA effector proteins HSC70 and LAMP-2A, which translocate to the lysosome for their degradation. Because LAMP-2A serves as a receptor for the selective uptake and degradation of the p53/HSC70 complex, we verified this interaction by immunoprecipitation using antibodies against p53 or LAMP-2A. A co-immunoprecipitation experiment verified an interaction between p53 with LAMP-2A or HSC70 during serum starvation (Supporting Fig. S4C). The expression of p53, Mdm2, and p21 levels under serum starvation conditions was examined by immunostaining of cultured Huh-7.5 cells (Supporting Fig. S4D). These results showed that both cytoplasmic and nuclear p53 staining decreased upon serum starvation. The expression of Mdm2 was induced in the nucleus under serum starvation. These results suggest that persistent HCV infection degrades p53 through CMA by inducing expression of cellular chaperones. The ER stress and CMA-mediated p53 degradation mechanisms shown in the infected cell culture were examined by western blot analysis using tissue extracts from cirrhotic explant livers with or without HCV infection. We found that the expression of p53 tumor suppressor was decreased among five out of eight HCV-infected explant livers (Fig. 6A). The expression of the ER stress chaperone (BIP), CMA-related proteins (HSC70, LAMP-2A), and Mdm2 was highly elevated in HCV-positive liver cirrhosis compared with HCV-negative cirrhotic samples (Fig. 6A,B). These results are consistent with our previous report showing the ER-stress response is induced in HCV-infected chronic liver diseases and liver cirrhosis. In summary, we were able to verify the significance of our experimental findings using HCV-infected PHHs and persistently infected Huh-7.5 cells.
with liver tissues derived from HCV-infected advanced cirrhosis.

**IFN-INDUCED HCV CLEARANCE NORMALIZES ER-STRESS RESPONSE AND RESTORES p53 MORE THAN DAAs**

Because the HCV-induced stress response degrades p53 by CMA mechanisms, we performed a comparative investigation to determine whether there is any difference in the p53 expression when HCV is cleared by either IFN or DAAs. First, persistently HCV-infected Huh-7.5 cells grown in six-well plates were given two rounds of IFN-α1 treatment at 3-day intervals. Then, HCV clearance from the infected culture was measured by Renilla luciferase activity. We observed that IFN-α1 significantly decreased HCV replication in the cell culture model (Fig. 7A). HCV clearance by IFN-α1 significantly decreased HCV NS3 expression and restored the expression of p53 and p21 by reducing the expression of ER-stress chaperones (BIP and HSC70) (Fig. 7B). Levels of glyceraldehyde 3-phosphate dehydrogenase remained the same in all the lanes. Second, we examined whether HCV clearance by RBV treatment could restore p53 expression. Persistently infected HCV culture was treated with two different concentrations of RBV, and the effect of viral clearance on p53 response was measured. We found that RBV inhibited HCV replication, which was determined by

![Graphs and Images](https://example.com/graphs/7.png)
FIG. 8. Expression of p53 in infected Huh-7.5 cells after repeated antiviral treatment. HCV-infected Huh-7.5 cells at day 9 were treated with either IFN-α, RBV, sofosbuvir, ledipasvir, or combined sofosbuvir plus ledipasvir. After 72 hours, cells were split and then treated again with the same antiviral agent. After five rounds of antiviral treatment, the expression of HCV, p53, and GAPDH levels was measured by western blot analysis. (A) Untreated HCV-infected culture. (B) IFN-α treated culture. (C) Ribavirin-treated culture. (D) Sofosbuvir-treated culture. (E) Ledipasvir-treated culture. (F) Combination treatment with sofosbuvir plus ledipasvir. (G) Hypothetical model showing that HCV clearance by DAA does not restore p53 in hepatocytes because DAAs themselves induce ER-stress. Abbreviation: GAPDH, glyceraldehyde 3-phosphate dehydrogenase; tx, treatment.
Renilla luciferase activity (Fig. 7C). Western blot analysis of the lysate prepared from the RBV-treated and untreated cultures showed that expression of p53 and p21 was not induced and levels of the ER stress markers BIP and HSC70 were not inhibited (Fig. 7D). Third, we examined the expression of p53, p21, and the stress response in an HCV-infected cell culture after sofosbuvir treatment. Infected culture was treated with sofosbuvir alone or sofosbuvir along with two different concentrations of RBV. Antiviral activity was measured by Renilla luciferase after two rounds of treatment (Fig. 7E). Cell lysates prepared from the treated and mock-treated cultures were examined for expression levels of p53, p21, BIP, and HSC70 by using western blot analysis. HCV clearance by either sofosbuvir alone or in combination with RBV did not restore p53 or p21 expression and did not reduce the expression of ER-stress chaperones (BIP and HSC70) (Fig. 7F). We examined whether HCV clearance by long-term repeated treatment with IFN-α could also decrease stress response compared with a DAA combination (Harvoni) currently approved for HCV treatment. In this experiment, HCV-infected liver tissue from patients with liver cirrhosis. Our findings are in agreement with a report showing that CMA degrades mutant p53 in a lysosome-dependent manner. We showed that CMA induces ER stress in uninfected Huh-7.5 cells. These results are consistent with previous publications that show a high expression of UPR genes in chronic liver disease and liver cirrhosis is related to HCV infection. We examined how HCV-infected hepatocytes manage ER stress without inducing cell death. Our results showed that persistent HCV replication improved cell survival pathways by inducing an autophagy response. It is not well established that HCV uses autophagy (macroautophagy) to promote viral RNA replication, translation, and virus production.

In this report, we found that persistent HCV replication induces CMA, as evidenced by the steady expression of HSC70 and LAMP-2A in an HCV culture after day 12. CMA induced by HCV degrades both wild-type p53 in PHHs and mutant p53 in Huh-7.5 cells. These results were verified using chronic HCV-infected liver tissue from patients with liver cirrhosis. Our findings are in agreement with a report showing that CMA degrades mutant p53 in a lysosome-dependent manner. We showed that inhibition of p53/Mdm2 interaction using nutlin-3 or silencing Mdm2 did not prevent degradation of p53 in an HCV-infected culture. LAMP-2A silencing restored p53 degradation in an HCV culture, suggesting that p53 degradation in an HCV-infected culture is mediated by lysosomal degradation. Our results provide a potential novel mechanism for how HCV regulates p53 in favor of its continued survival.

Chronic HCV infection is one of the risk factors for developing liver cirrhosis and HCC. The risk of HCC is very high among patients with advanced liver fibrosis/cirrhosis. Recent reviews summarize the importance of p53 in HCV-induced HCC mechanisms and how
HCV infection alters p53 functions by many different pathways. Rusyn and Lemon claimed that the majority of publications show that HCV replication represses p53 functions. Tomohiro et al. showed that 24-dehydrocholesterol reductase is elevated in response to HCV infection and inhibits p53 by stimulating the accumulation of the Mdm2-p53 complex in the cytoplasm and by inhibiting the acetylization of p53 in the nucleus. A study by Duong et al. reported that p53 can be inactivated through induced expression of protein phosphatase 2A. They showed HCV transgenic mice that overexpress protein phosphatase 2A develop larger tumors after diethylaminoamine treatment. We now provide new evidence suggesting that HCV-induced ER-stress response promotes rapid degradation of p53 to improve cellular surveillance. The degradation of p53 was also seen when nonviral agents induced ER stress and autophagy. As the loss of p53 function is associated with the majority of human cancers, our findings may contribute to understanding the HCV-induced HCC mechanism.

The availability of new IFN-free DAAs dramatically increased sustained virological response among patients with hepatitis C virus infection. It is anticipated that an increased number of patients will be able to clear infection with this new medication. At present, only a few studies have investigated the risk factor for HCC after eradication of the virus infection by DAA-based therapy among patients with advanced liver cirrhosis. These clinical studies show that the risk of HCC is greater after HCV cure by DAAs compared to IFN-based antiviral therapy. In this study, we compared the rate of the ER-stress response and restoration of the p53 tumor suppressor in infected culture after HCV clearance. We found that HCV clearance by IFN-α or IFN-λ is able to induce expression of p53 and normalize the ER-stress response. However, DAA treatment inhibited HCV replication but did not inhibit the ER-stress response or restore p53 expression. We noted that IFN-induced HCV clearance restores the p53 level significantly better than ribavirin, sofosbuvir, and ledipasvir. Our results suggest that unresolved ER stress after HCV clearance by DAAs continues to suppress p53 expression, which could increase the risk for HCC development.

Acknowledgment: The authors acknowledge Samantha Hoekstra, Department of Pathology, Tulane University Health Sciences Center, for critically reading this manuscript. The authors are grateful to Shuanghu Liu, M.D., Ph.D. and Curt H. Hagedorn, M.D., University of Utah School of Medicine, Salt Lake City, UT, for supplying the HCV-GFP reporter virus used in the co-localization studies. Yucel Aydin was supported by funds received from the Akdamar Fellowship Program, Department of Gastroenterology and Hepatology, Tulane University Health Sciences Center.

REFERENCES

1) Reig M, Marino Z, Perello C, Inarairaequi M, Ribeiro A, Lens S, et al. Unexpected high rate of early tumor recurrence in patients with HCV related HCC undergoing interferon-free therapy. J Hepatol 2016;65:719-726.
2) Conti F, Buonfiglioli F, Scotteri A, Crespi C, Bolondi L, Caraceni P, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct acting antivirals. J Hepatol 2016;65:727-733.
3) Cheung MC, Walker AJ, Hudson BE, Verma S, McLachlan J, Mutimer DJ, et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016;65:741-747.
4) El-Serag HB, Kanwal F, Richardson P and Kramer J. Risk of hepatocellular carcinoma after sustained virological response in Veterans with Hepatitis C virus infection. Hepatology 2016;64:130-137.
5) Wang M and Kaufman RJ. The impact of the endoplasmic reticulum protein-folding environment on cancer development. Nat Rev Cancer 2014;14:581-597.
6) Sato Y and Tsurumi T. Genome guardian p53 and viral infections. Rev Med Virol 2013;23:213-220.
7) Horner SM, Gale M Jr. Regulation of hepatic innate immunity by hepatitis C virus. Nat Med 2013;19:879-888.
8) Zang A, Wei J, Noto JM, Peak RM. Microbial Regulation of p53 tumor suppressor. PLOS Pathog 2015;11:e1005099.
9) Dash S, Chava S, Aydin Y, Chandra P, Ferrari P, Chen W, et al. Review: Hepatitis C virus infection induces autophagy as a prosurvival mechanism to alleviate hepatic ER stress response. Viruses 2016;8 pii:E150.
10) Chandra PK, Bao L, Song K, Aboulnasr FM, Baker DP, Shores N, et al. HCV infection selectively impairs type I but not type III IFN signaling. Ann J Pathol 2014;184:214-229.
11) Panigrahi R, Chandra PK, Ferraris P, Kirt R, Song K, Garry RF, et al. Persistent hepatitis C virus infection impairs ribavirin antiviral activity through clathrin-mediated trafficking of equilibrative nucleoside transporter 1. J Virol 2015;89:626-642.
12) McCloy RA, Rogers S, Caldron CE, Lorca T, Castro A, Burgess A. Partial inhibition of Cdk1 in G2 phase overrides the SAC and decouples mitotic events. Cell Cycle 2014;13:1400-1412.
13) Jensen EJ. Quantitative analysis of histological staining and fluorescence using ImageJ. Anat Rec 2013;296:378-381.
14) Boya P, Reggiori F, Codogno P. Emerging regulation and functions of autophagy. Nat Cell Biol 2013;15:713-720.
15) Artis E, Cuervo AM. Chaperone-mediated autophagy in protein quality control. Curr Opin Cell Biol 2011;23:184-189.
16) Meng X, Franklin DA, Dong J, Zhang Y. MDM2-p53 pathway in hepatocellular carcinoma. Can Res 2014;74:7161-7167.
17) Vakifahmetogle-Norberg H, Kim M, Xia HG, Iwanicki MP, Ofengeim D, Coloff JL, et al. Chaperon-mediated autophagy degrades mutant p53. Genes Dev 2013;27:1718-1730.

18) Liu S, Xiao L, Nelson C, Hagedorn CH. A cell culture adapted HCV JFH1 variant that increases viral titers and permits the production of high titer infectious chimeric reporter viruses. PLoS One 2012;7:e44965.

19) Chandra PK, Gunduz F, Hazari S, Kurt R, Panigrahi R, Poat B, et al. Impaired expression of type I and type II interferon receptors in HCV-associated chronic liver disease and liver cirrhosis. PLoS One 2014;9:e108616.

20) Asselah T, Bieche I, Mansouri A, Laurendeau I, Cazals-Hatem D, Feldmann G, et al. In vivo hepatic endoplasmic stress in patients with chronic hepatitis C. J Pathol 2010;221:264-274.

21) Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006;6:674-687.

22) Rusyn I, Lemon SM. Mechanisms of HCV induced liver cancer: what did we learn from in vitro and animal studies. Cancer Lett 2014;345:210-215.

23) Nishimura T, Kohara M, Isumi K, Kasama Y, Hirata Y, Huang Y, et al. Hepatitis C virus impairs p53 via persistent overexpression of 3beta-hydroxysterol Delta24-reductase. J Biol Chem 2009;284:36442-36452.

24) Duong FH, Dill MT, Matter MS, Makowska Z, Calabrese D, Dietsche T, et al. Protein phosphatase 2A promotes hepatocellular carcinogenesis in the diethylnitrosamine mouse model through inhibition of p53. Carcinogenesis 2014;35:114-122.

Supporting Information

Additional Supporting Information may be found at onlinelibrary.wiley.com/doi/10.1002/hep4.1025/suppinfo.